ClinicalTrials.gg

Program

HM15275

A development code.

Its studies are mostly in Obesity · Diabetes Mellitus, Type 2, led by Hanmi Pharmaceutical.

Furthest: phase 2, since Sep 16, 20253 company-led studies, 2 open or runningNext primary completion: Jan 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hanmi Pharmaceutical32 open or runningphase 2since Sep 16, 2025May 30, 2024Jan 2027phase 2 · NCT07205900

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 30, 2024First study: phase 1 study in ObesityFirst studyNCT06481098 · 74 enrolled · United States
  2. Sep 16, 2025Phase 2 study in ObesityNCT07205900 · 267 enrolled · United States
  3. Apr 7, 2026Phase 2 study in Diabetes Mellitus, Type 2NCT07527650 · 180 planned · United States

Ahead

  1. Jan 2027Primary completion: phase 2 study in ObesityNCT07205900
  2. Oct 2027Primary completion: phase 2 study in Diabetes Mellitus, Type 2NCT07527650

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07527650Diabetes Mellitus, Type 2 · United States2RecruitingOct 2027180
NCT07205900Obesity · United States2Active, not recruitingJan 2027267
NCT06481098Obesity · United States1CompletedMay 2, 202574

How it is read

Names in the registry

  • “HM15275”, 3 entries

Codes read as this program: HM15275.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.